You are here: Home > Products > Cervical Cancer Biom... > CDx-ICC Plus

CDx-ICC Plus

CDx-ICC Plus is developed to detect the HPV oncogenic protein biomarker and a proliferation index protein for more precise and sensitive detection of high-grade precancerous cervical lesions.

Suitable for Liquid-based cytology (e.g. ThinPrep) and traditional Pap smear cervical cells samples.

Cervical Cancer

Cervical cancer is the second most common malignant tumor in women worldwide. There are about 520,000 new cases and more than 270,000 such cancer-associated deaths every year. In low-income countries, it is the most common cause of cancer death in women.
About 70% of cervical cancers occur in developing countries, where the lack of screening is the main reason of high mortality in cervical cancer. However, cervical cancer is highly preventable. Typically, the development of a precancerous lesion to cancer stage takes over 10 years or longer. Therefore, if the routine screening is implemented and pre-cancer found and treated early, the mortality rate can be reduced, and patient’s outcome and 5-year disease-free survival can be significantly improved.
China has more than 400 million population of women in the age group 21 to 65-yr, who need to receive routine screening tests in order to reduce the cancer incidence rate.

HPV infections are very common and cause virtually all cervical cancer. However,only women with persistent infections from high-risk HPV (hr-HPV) strains and have developed high-grade precancerous disease should be treated.